Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Baricitinib Placebo
DRUG
2 trials
Sponsors
Eli Lilly and Company
Conditions
Rheumatoid Arthritis
Phase 3
A Study in Moderate to Severe Rheumatoid Arthritis
Completed
NCT01710358
Eli Lilly and Company
Rheumatoid Arthritis
Start: 2012-10-31
End: 2015-09-30
Updated: 2019-09-18
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
Completed
NCT01711359
Eli Lilly and Company
Rheumatoid Arthritis
Start: 2012-11-30
End: 2015-08-31
Updated: 2019-09-19
Related Papers
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study.
2024-10-01
4 citations
P127 Baricitinib Efficacy in Moderate Rheumatoid Arthritis - A Post-hoc Analysis from two Phase III Trials
Lara D. Veeken
2023-04-01
Relative Impact of Pain and Disease Activity on Improvements in Fatigue
JCR Journal of Clinical Rheumatology
2022-12-06
2 citations
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
RMD Open
2022-03-01
25 citations
Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
ACR Open Rheumatology
2021-12-16
7 citations
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
2021-10-27
107 citations
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND
The Journal of Rheumatology
2021-09-15
7 citations
Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
Arthritis Research & Therapy
2020-05-15
16 citations
Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial.
2019-06-21
20 citations
<p>Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain</p>
ClinicoEconomics and Outcomes Research
2019-06-01
11 citations
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
Annals of the Rheumatic Diseases
2019-04-30
24 citations
Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.
2019-03-22
35 citations
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Modern Rheumatology
2019-02-20
54 citations
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
The Journal of Rheumatology
2018-09-15
251 citations
Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis
Rheumatology and Therapy
2018-04-21
5 citations
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
2018-02-20
44 citations
Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials.
2018-02-02
13 citations
Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.
2018-01-13
9 citations
Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
2017-09-18
46 citations
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
2017-08-10
83 citations
2 more papers not shown